NEW YORK, July 18 (Praxis Press) A new class of nonsteroidal anti-inflammatory drugs selectively inhibits cyclooxygenase (COX)-2 and may produce fewer adverse effects than nonselective inhibitors.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback